News

August 24, 2020August 24, 2020

FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma after one to three lines of therapy. Specifically, Darzalex ... Read more

August 17, 2020August 17, 2020

Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial

News

Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without disease worsening, when added to a combination of Pomalyst (pomalidomide) and ... Read more

August 12, 2020August 12, 2020

HealthTree University Opens to Help Myeloma Patients Better Direct Their Care

News

The online portal HealthTree has opened a free and online patient resource connecting multiple myeloma experts from around the world with patients to help them better understand their disease, so ... Read more

August 10, 2020August 11, 2020

Ide-cel Application Resubmitted to FDA With Requested Data

News

Bristol Myers Squibb and Bluebird Bio have resubmitted a biologics license application (BLA) with additional information requested by the U.S. Food and Drug Administration to consider the approval of idecabtagene vicleucel (ide-cel) for adults with hard-to-treat multiple ... Read more

August 7, 2020August 7, 2020

FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with relapsed or refractory multiple myeloma, its developer, ... Read more

July 31, 2020July 31, 2020

Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an investigational treatment for relapsed or refractory multiple ... Read more

July 29, 2020July 29, 2020

First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients

News

A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or refractory multiple myeloma, has dosed its first patient, SpringWorks ... Read more

July 27, 2020September 21, 2020

EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma

News

GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma ... Read more

July 24, 2020July 24, 2020

$1.9M Grant Awarded for Study on How Fat Cells Help Myeloma Cells Resist Treatment

News

A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from the National Cancer Institute of ... Read more

July 22, 2020July 22, 2020

Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show

News

A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or refractory multiple myeloma, interim results from a ... Read more

Pin It on Pinterest